目的 探討玉泉顆粒聯(lián)合恩格列凈片治療2型糖尿病的臨床療效。方法 選取2020年7月—2022年6月上海建工醫(yī)院收治144例2型糖尿病患者，按照隨機(jī)數(shù)字表法將所有患者分為對(duì)照組和治療組，每組各72例。對(duì)照組口服恩格列凈片，1片/次，1次/d；治療組在對(duì)照組治療基礎(chǔ)上口服玉泉顆粒，1袋/次，4次/d。兩組連續(xù)治療1個(gè)月。觀察兩組的臨床療效，比較兩組的空腹血糖（FPG）、糖化血紅蛋白（HbA1c）、平均血糖（MBG）、餐后血糖波動(dòng)幅度（PPGE）、血糖水平標(biāo)準(zhǔn)差（SDBG）、胰島素抵抗指數(shù)（HOMA-IR）、胰島β細(xì)胞功能指數(shù)（HOMA-β）以及血清晚期氧化蛋白終產(chǎn)物（AOPP）、糖基化終末產(chǎn)物（AGES）、氧化型低密度脂蛋白受體-1（LOX-1）水平。結(jié)果 治療后，治療組總有效率94.44%高于對(duì)照組總有效率81.94%，組間比較差異顯著（P＜0.05）。治療后，兩組FPG、HbA1c、MBG、PPGE、SDBG低于治療前（P＜0.05）；治療組的MBG、PPGE、SDBG低于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P＜0.05）。治療后，兩組HOMA-IR低于治療前，HOMA-β高于治療前（P＜0.05）；治療組的HOMA-IR低于對(duì)照組，HOMA-β高于對(duì)照組（P＜0.05）。治療后，兩組的血清AOPP、AGES、LOX-1水平低于治療前（P＜0.05），且治療組血清AOPP、AGES、LOX-1水平較對(duì)照組低（P＜0.05）。結(jié)論 玉泉顆粒聯(lián)合恩格列凈片治療2型糖尿病的臨床療效確切，能改善血糖波動(dòng)和胰島素β細(xì)胞功能，降低氧化應(yīng)激反應(yīng)。

Objective To investigate the clinical efficacy of Yuquan Granules combined with Empagliflozin Tablets in treatment of type 2 diabetes mellitus. Methods Patients (114 cases) with type 2 diabetes mellitus in Shanghai Construction Group Hospital from July 2020 to June 2022 were divided into control and treatment groups according to the random number table method, and each group had 72 cases. Patients in the control group were po administered with Empagliflozin Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Yuquan Granules on the basis of the control group, 1 bag/time, four times daily. Patients in two groups were treated for 1 month. After treatment, the clinical efficacies were evaluated, and the FPG HbA1c, MBG, PPGE, SDBG, HOMA-IR, and HOMA-β, and the levels of AOPP, AGES, and LOX-1 in two groups were compared. Results After treatment, the total effective rate of the treatment group was 94.44% higher than 81.94% of the control group, and there was a significant difference between groups (P < 0.05). After treatment, FPG, HbA1c, MBG, PPGE, and SDBG in two groups were lower than those before treatment (P < 0.05). MBG, PPGE, and SDBG in the treatment group were lower than those in the control group, and the difference was statistically significant (P < 0.05). After treatment, HOMA-IR in two groups was lower than before treatment, but HOMA-β in two groups was higher than before treatment (P < 0.05). HOMA-IR in treatment group was lower than that in control group, but HOMA-β in treatment group was higher than that in control group (P < 0.05). After treatment, the serum levels of AOPP, AGES, and LOX-1 in two groups were lower than those before treatment (P < 0.05), and the serum levels of AOPP, AGES, and LOX-1 in the treatment group were lower than those in the control group (P < 0.05). Conclusion Yuquan Granules combined with Empagliflozin Tablets has clinical curative effect in treatment of type 2 diabetes mellitus, can improve blood sugar fluctuation and insulin beta cell function, reduce oxidative stress.

R977

上海市虹口區(qū)衛(wèi)生計(jì)劃生育委員會(huì)醫(yī)學(xué)科研課題（1503-23）